Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Healthcare Biotechnology
Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Covalon Technologies Ltd
Bullboard Posts
User Avatar Image
(11)
•••
Post by zenvestingon Jul 11, 2014 9:48am
213 Views
Post# 22736208

COV = Value in Advanced Wound Care

COV = Value in Advanced Wound CareCovalon (COV) has a trailing P/Eof less than 15 (including the up front licensing payment) , a forward P/E of less than 30 (before the licensee had even "debuted" the new products, and $4.2M cash and equivalents in the bank.

Compare COV to U.S. listed advanced wound care companies such as ALQA, DSCI, MDWD, OCLS, SNWV, or WNDM. COV is the only company turning a profit, yet these other companies are trading with market caps that are multiples higher than Covalons.

Oh, about Molnlycke just recently "debut"ing the new product, that's their terms for their presentation at WOCN in late June:
https://wocnconference.com/wocn2014/Public/eBooth.aspx?BoothID=100572&Task=Videos&VideoID=4

Also interesting, Molnlycke made dedicated webistes for their new products, where they haven't done that for their original Mepitel Film product line and very few of their other products?:
https://www.mepitelfilmivam.com/
https://www.mepitelfilmam.com/index.html


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities